The company is currently focused on developing namilumab (IZN-101), a monoclonal antibody therapy targeting granulocyte macrophage-colony stimulating factor (GM-CSF) for the treatment of ankylosing spondylitis (AS), an incurable and painful type of arthritis. AS affects the spine and can significantly reduce mobility and quality of life. IZN-101 is a novel new treatment in development for AS, offering patients an alternative approach to current therapies. The company is preparing to run a Phase II study of IZN-101 in the UK to demonstrate its efficacy in improving clinical symptoms, inflammation markers, and MRI appearance of the spine in patients with moderately to severely active AS.